Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 16/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45447 | 1.00 | CASP1 (0.59) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL2619551 | 1.00 | CASP1 (0.59) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL30947821 | 0.92 | CASP1 (0.62) | CASP1SYKCTSLCTSBCTSS | |
| SCHEMBL13324038 | 0.92 | CTSL (0.58) | CTSKCTSLCTSBCTSS | |
| SCHEMBL14385711 | 0.90 | SYK (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL6078490 | 0.90 | SYK (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL6078485 | 0.90 | SYK (0.56) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL5033775 | 0.90 | PPARA (0.58) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL1093029 | 0.90 | PPARA (0.58) | CASP1SYKCTSKCTSLCTSB | |
| SCHEMBL3004720 | 0.90 | PPARA (0.58) | CASP1SYKCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583887-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12559521-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240425547-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240409580-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12139554-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12122851-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230174562-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | Tonix Pharmaceuticals, Inc. | 2023-06-08 | — | — | US | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258134-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2018-09-13 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-08 | — | — | US | disclosed |
| US-20160304555-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| CN-101541800-A | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer | CHROMA THERAPEUTICS LTD (GB) | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425547-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | GOT2, GOT1, OTC | CASP1 1698/4885SYK 4806/4885CTSK 3711/4885 |
| US-20230174562-A1 | RADIO-AND CHEMO-PROTECTIVE COMPOUNDS | MGMT, RCOR3, TSPO | CASP1 99/4885SYK 4867/4885CTSK 1976/4885 |
| US-20180000952-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | CASP1 2960/4885SYK 1716/4885CTSK 723/4885 |
| US-20180258134-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-20240409580-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-12559521-B2 | PSMA imaging agents | KLK3, PSMA1, PSMA6 | CASP1 3525/4885SYK 4434/4885CTSK 824/4885 |
| US-12139554-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-12583887-B2 | PSMA imaging agents | KLK3, PSMA3, PSMA1 | CASP1 4037/4885SYK 4295/4885CTSK 965/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | CASP1 2960/4885SYK 1716/4885CTSK 723/4885 |
| US-10011632-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-12122851-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | GOT2, GOT1, OTC | CASP1 1698/4885SYK 4806/4885CTSK 3711/4885 |
| US-20160304555-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | CASP1 4534/4885SYK 4321/4885CTSK 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.